Skip to content

Ketamine research published in 2014

Page 2 of 3: studies 21 to 40 of 50, newest first. Back to the ketamine overview

Studies

Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users

International Journal of Drug Policy July 15, 2014 Hanna Uosukainen, Ulrich Tacke, Adam Winstock 55 citations

BackgroundEvidence regarding MDMA (ecstasy) dependence and the most suitable criteria for its assessment are controversial. This study aimed to assess the prevalence of last year symptoms of dependence upon MDMA compared to cocaine, mephedrone and ketamine among a large global non-treatment seeking sample.MethodsA cross-sectional anonymous online survey was promoted by a UK-based dance music...

Ketamine (IM) Assisted Psychotherapy (KAP): A Model for Informed Consent

International Journal of Transpersonal Studies July 1, 2014 Philip E. Wolfson

A Model for Informed ConsentInformed consent is important for every medical intervention, and the unique nature of ketamine assisted psychotherapy (KAP) calls for a particularly thoughtful and detailed informed consent document.The following is an informed consent form developed for the author's use in his own private practice.No representations are made concerning its adequacy or...

Regarding the Transpersonal Nature of Ketamine Therapy: An Approach to the Work

International Journal of Transpersonal Studies July 1, 2014 Jeffrey Becker 8 citations

Recent evidence has shown that ketamine treatment can facilitate psychological insight and symptom resolution in various psychiatric disorders.To aid this process, psychotherapeutic support should be considered a fundamental aspect of treatment.The psychedelic experience produced by ketamine can be a deeply meaningful source of enduring change and personal growth.The author has repeatedly...

Ethnographic Accounts of Ketamine Explorations in Psychedelic Culture

International Journal of Transpersonal Studies July 1, 2014 Kenneth Ring, Ralph Metzner, Philip E. Wolfson 1 citation

Off-label use of ketamine as a mind-altering substance did not begin in the laboratory, but in the psychedelic culture that grew out of the 1960s counterculture movement. Whatever the risks and limitations of such experimentation, without them the remarkable therapeutic effects of the drug might well have gone unnoticed, and unresearched. The following personal accounts-both inspiring and...

DOI: 10.24972/ijts.2014.33.2.175 (opens in new tab) Ketamine Counterculture Ethnography Aesthetics +2

The Transformative Power of Ketamine: Psychedelic States and a Personal History of Transformation

International Journal of Transpersonal Studies July 1, 2014 Philip E. Wolfson 4 citations

A discussion of the nature of transformation and its relationship to psychedelic experiencesparticularly ketamine experiences-is presented and discussed along with a schema for thinking about types of states that may be encountered and transformations that may occur related to psychedelic use and practice. This is followed by a longitudinal historical approach for portraying and examining...

DOI: 10.24972/ijts.2014.33.2.193 (opens in new tab) Transformative learning Transformational leadership Schema genetic algorithms Transformation genetics +3

Ketamine for Depression: A Mixed-Methods Study

International Journal of Transpersonal Studies July 1, 2014 Philip E. Wolfson 2 citations

Prior studies have reported variously on the presence or absence of dissociative effects at subanesthtetic doses of ketamine administered for treatment-resistant depression. This mixedmethods study emulated the protocol used for the studies in question, with IV administration of 0.5mg/kg over 40 minutes with eight experienced ketamine users. Quantitative measures were generally insignificant...

Ketamine Dependence in an Anesthesiologist: An Occupational Hazard?

Indian Journal of Psychological Medicine July 1, 2014 S. Goyal, A. Ambekar, R. Ray 21 citations

Substance abuse among medical professionals is a cause for concern. Certain psychotropic substances such as ketamine are at easy dispense to anesthesiologists increasing the likelihood of misuse and dependence and raise several issues including safety of patients. We discuss a case demonstrating ketamine dependence in an anesthesiologist from India. The reported psychotropic effects of ketamine...

Ketamine and Depression: A Review

International Journal of Transpersonal Studies July 1, 2014 Wesley C Ryan, Cole Marta, Ralph J. Koek 5 citations

Ketamine, via intravenous infusions, has emerged as a novel therapy for treatment-resistant depression, given rapid onset and demonstrable efficacy in both unipolar and bipolar depression. Duration of benefit, on the order of days, varies between these subtypes, but appears longer in unipolar depression. A unique property is reduction in suicidality although data are more limited. Strategies to...

Psychedelic Experiential Pharmacology: Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too): An Interview with Richard Yensen

International Journal of Transpersonal Studies July 1, 2014 Philip E. Wolfson 20 citations

Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stanislav Grof, M.D. and other senior staff. During this time he treated patients with substance abuse disorders, cancer, neurosis, and other health professionals seeking a training experience. Dr. Yensen did his Ph.D. dissertation on the use of MDA in...

DOI: 10.24972/ijts.2014.33.2.160 (opens in new tab) Ketamine Experiential learning Psychoanalysis Psychotherapist

Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications

International Journal of Transpersonal Studies July 1, 2014 Eli Kolp, Harris L. Friedman, Evgeny Krupitsky et al. 53 citations

Meant to be an authoritative guide for psychiatrists and others interested in understanding and applying ketamine psychedelic psychotherapy (KPP), this paper focuses on its pharmacology, phenomenology, and clinical applications. Ketamine is a dissociative anesthetic widely used by physicians and veterinarians in the United States. In addition to its anesthetic and dissociative properties,...

Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine

Pharmacopsychiatry June 23, 2014 Nancy B. Lundin, Mark J. Niciu, David A. Luckenbaugh et al. 17 citations

INTRODUCTION: Deficiencies in both vitamin B12 and folate have been associated with depression. Recently, higher baseline vitamin B12 levels were observed in individuals with bipolar depression who responded to the antidepressant ketamine at 7 days post-infusion. This study sought to -replicate this result by correlating peripheral vitamin levels with ketamine's antidepressant efficacy in...

Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic

Journal of Psychopharmacology June 1, 2014 Peter R Diamond, Andrew D Farmery, Stephanie Atkinson et al.

Background: Ketamine has a rapid antidepressant effect in treatment-resistant depression (TRD). The effects on cognitive function of multiple ketamine infusions and of concurrent antidepressant medication on response rate and duration are not known. Method: Twenty-eight patients with uni- or bipolar TRD were treated over three weeks with either three or six ketamine infusions (0.5 mg/kg over 40...

Brain damages in ketamine addicts as revealed by magnetic resonance imaging

Frontiers in Neuroanatomy May 22, 2014 Chunmei Ewang, Dong Ezheng, Jie Exu et al. 123 citations

Ketamine, a known antagonist of N-methyl-D-aspartic (NMDA) glutamate receptors, had been used as an anesthetic particularly for pediatric or for cardiac patients. Unfortunately, ketamine has become an abusive drug in many parts of the world while chronic and prolonged usage led to damages of many organs including the brain. However, no studies on possible damages in the brains induced by...

THE METABOTROPIC GLUTAMATE 2/3 RECEPTOR AGONIST LY379268 COUNTERACTED KETAMINE-AND APOMORPHINE-INDUCED PERFORMANCE DEFICITS IN THE OBJECT RECOGNITION TASK, BUT NOT OBJECT LOCATION TASK, IN RATS

Neuropharmacology May 20, 2014 N. Pitsikas, A. Markou

Experimental evidence indicates that the non competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine and the mixed dopamine (DA) D1/D2 receptor agonist apomorphine induce schizophrenia-like symptoms in rodents, including cognitive deficits. Activation of Group II metabotropic glutamate 2/3 (mGlu2/3) receptors reduces the excessive glutamate release that is hypothesized to be...

Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression

The Journal of Clinical Psychiatry May 15, 2014 Mark J. Niciu, David A. Luckenbaugh, Dawn F. Ionescu et al. 167 citations

OBJECTIVE: The N-methyl-D-aspartate receptor antagonist ketamine has rapid antidepressant effects in treatment-resistant major depressive disorder (MDD) and bipolar depression. Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations. METHOD: Data were analyzed from 4 studies of treatment-resistant inpatients with...

Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder

JAMA Psychiatry April 16, 2014 Adriana Feder, Michael K. Parides, James W. Murrough et al. 618 citations

IMPORTANCE: Few pharmacotherapies have demonstrated sufficient efficacy in the treatment of posttraumatic stress disorder (PTSD), a chronic and disabling condition. OBJECTIVE: To test the efficacy and safety of a single intravenous subanesthetic dose of ketamine for the treatment of PTSD and associated depressive symptoms in patients with chronic PTSD. DESIGN, SETTING, AND PARTICIPANTS:...

A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.

British Journal of Pharmacology April 1, 2014 A Villaseñor, A Ramamoorthy, M Silva Dos Santos et al. 69 citations

(R,S)-ketamine produces rapid and significant antidepressant effects in approximately 65% of patients suffering from treatment-resistant bipolar depression (BD). The genetic, pharmacological and biochemical differences between ketamine responders and non-responders have not been identified. The purpose of this study was to employ a metabolomics approach, a global, non-targeted determination of...

DOI: 10.1111/bph.12494 (opens in new tab) Full text (opens in new tab) Fatty acid metabolism Lithium Mitochondrial function Pharmacometabolomics +1

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION

Depression and Anxiety March 25, 2014 Rebecca B Price, Dan V. Iosifescu, James W. Murrough et al. 342 citations

BACKGROUND: Preliminary evidence suggests intravenous ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide. In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit...

DOI: 10.1002/da.22253 (opens in new tab) Ketamine Suicidal ideation Beck depression inventory Cognition +7

Ketamine – More mechanisms of action than just NMDA blockade

Trends in Anaesthesia and Critical Care March 22, 2014 Jamie Sleigh, Martyn Harvey, Logan J. Voss et al. 441 citations

Ketamine has been in clinical use for over half a century, yet its precise mechanisms of action remain mysterious for the large part. Its hypnotic effects appear to be largely mediated by blockade of NMDA and HCN1 receptors, but cholinergic, aminergic, and opioid systems appear to play both a positive and negative modulatory role in both sedation and analgesia. Ketamine's effects in chronic...

DOI: 10.1016/j.tacc.2014.03.002 (opens in new tab) Ketamine Glutamatergic Nmda receptor Blockade +8